Lupin Q2 results: Net profit falls 22% to ₹1,155 cr, revenue at ₹7,827 cr
Indian markets moved higher in a quarterly results development for FY27 with September 30 in focus.
· BS Companies
Homegrown pharma major Lupin on Wednesday posted a 22.19 per cent decline in consolidated net profit to Rs 1,155.30 crore in the September quarter, dragged down by an exceptional item. The company had posted a net profit of Rs 1,484.83 crore in the corresponding period of the previous fiscal year, it said in a regulatory filing to the exchanges.
Key facts
- Period
- FY27
- Dates in focus
- September 30
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- Sectors in the story: Pharma & Healthcare.
Pharma & Healthcare
1M +1.1% · 3M -0.5%
Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Q2 Results Live: Pfizer's One-Time Gain Lifts Profit; SBI Asset Quality Improves; Solar Industries Profit Zooms 79%
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Stocks to watch: ITC, Lupin, NBCC, SBI, Dr Reddy's, Bosch, Ola Electric
Why is market rallying today? Sensex soars over 950 pts, Nifty tops 23,300. 7 factors driving Rs 4 lakh crore D-Street gains